rifaximin + sodium phosphate + polyethylene glycol

Rifaximin, in combination with sodium phosphate enema and polyethylene glycol, is being investigated by Torre Médica Santé for the treatment of motor complications in Parkinson's disease, specifically levodopa-induced dyskinesia (LID) and motor fluctuations. This therapeutic approach, termed intestinal decontamination or gut microbiota modification, targets abnormalities in the gut microbiome that may contribute to the motor manifestations of the disease via the gut-brain axis. Rifaximin is a non-absorbable, broad-spectrum antibiotic that inhibits bacterial RNA synthesis by binding to the beta-subunit of DNA-dependent RNA polymerase. In the Phase 1 clinical trial (NCT04730245), the regimen involved a hospital-administered sodium phosphate enema followed by a 7-day course of oral rifaximin (200 mg three times daily) and a 10-day course of polyethylene glycol to modify the intestinal environment and potentially improve the response to dopaminergic therapy.

Other names

intestinal decontamination therapygut microbiota modification therapy